Comparison of baseline characteristics by EOT PET
| Characteristic . | All patients (n = 723), n (%) . | PET-NEG (n = 517), n (%) . | PET-POS (n = 206), n (%) . | P . |
|---|---|---|---|---|
| Age >60 years | 460 (64) | 333 (64) | 127 (62) | .49 |
| Male | 411 (57) | 289 (56) | 122 (59) | .42 |
| ECOG PS 2-4 | 299 (41) | 203 (41) | 96 (47) | .15 |
| Stage III/IV | 534 (74) | 389 (75) | 145 (70) | .18 |
| B symptoms | 320 (44) | 207 (40) | 113 (55) | <.001 |
| Marrow involvement | 77 (11) | 63 (12) | 14 (7) | .03 |
| Elevated LDH | 393 (54) | 257 (54) | 136 (69) | <.001 |
| Extranodal sites >1 | 221 (31) | 165 (44) | 56 (38) | .15 |
| Bulky site ≥10 cm | 285 (39) | 172 (33) | 113 (55) | <.001 |
| Skeletal involvement | 142 (20) | 103 (20) | 39 (19) | .76 |
| Craniofacial involvement | 41 (6) | 33 (6) | 8(4) | .19 |
| Hemoglobin <110 g/L | 191 (26) | 124 (26) | 67 (35) | .02 |
| IPI 3-5 | 377 (52) | 260 (55) | 117 (59) | .33 |
| Characteristic . | All patients (n = 723), n (%) . | PET-NEG (n = 517), n (%) . | PET-POS (n = 206), n (%) . | P . |
|---|---|---|---|---|
| Age >60 years | 460 (64) | 333 (64) | 127 (62) | .49 |
| Male | 411 (57) | 289 (56) | 122 (59) | .42 |
| ECOG PS 2-4 | 299 (41) | 203 (41) | 96 (47) | .15 |
| Stage III/IV | 534 (74) | 389 (75) | 145 (70) | .18 |
| B symptoms | 320 (44) | 207 (40) | 113 (55) | <.001 |
| Marrow involvement | 77 (11) | 63 (12) | 14 (7) | .03 |
| Elevated LDH | 393 (54) | 257 (54) | 136 (69) | <.001 |
| Extranodal sites >1 | 221 (31) | 165 (44) | 56 (38) | .15 |
| Bulky site ≥10 cm | 285 (39) | 172 (33) | 113 (55) | <.001 |
| Skeletal involvement | 142 (20) | 103 (20) | 39 (19) | .76 |
| Craniofacial involvement | 41 (6) | 33 (6) | 8(4) | .19 |
| Hemoglobin <110 g/L | 191 (26) | 124 (26) | 67 (35) | .02 |
| IPI 3-5 | 377 (52) | 260 (55) | 117 (59) | .33 |
Bold P values indicate statistical significance.
ECOG, European Cooperative Oncology Group; IPI, International Performance Index; LDH, lactate dehydrogenase.